International Psoriasis Council

International Psoriasis Council
subscribe
5   What's New
Search
subscribe
Search

Advancing Knowledge. Improving Care.

Meet Our Newest Councilors

IPC is pleased to introduce and welcome our five newest Councilors for 2022: Pravit Asawanonda, Sunil Dogra, Benjamin Ehst, Filip Rob, and Tsen-Fang Tsai. These individuals were confirmed by the IPC Board of Directors during the European Academy of Dermatology and Venereology (EADV) Congress in September. They bring a diverse and broad experience in the field of psoriasis and are passionate about working to improve care for psoriasis patients around the world. IPC Councilors serve in an advisory capacity and lend their global expertise on psoriasis research, treatment, and education to support all IPC programs, events, and initiatives. They are selected based on their overall reputation in the dermatology community, experience in clinical or investigative research in psoriasis, level of clinical expertise in patient care, and demonstrated professional interest in psoriasis. Learn more about IPC Councilors and read their full biographies.

Our Newest Councilors

Pravit Asawanonda, MD, MSc, DSc

Chulalongkorn University

Bangkok, Thailand

IPC Councilor

Bio

Sunil Dogra, MD, DNB, FAMS, FRCP

Postgraduate Institute of Medical Education & Research

Chandigarh, India

IPC Councilor

Bio

Benjamin Ehst, MD, PhD

Oregon Medical Research Center

Portland, Oregon, United States

IPC Councilor

Bio

Filip Rob, MD, PhD

Charles University

Prague, Czech Republic

IPC Councilor

Bio

Tsen-Fang Tsai, MD

National Taiwan University Hospital

Taipei, Taiwan

IPC Councilor

Bio

Categories

Recent Posts

Next Generation of Leaders: 2025 IPC Fellows Transition to Jr. Councilors

VIEW

Highlights from the 2026 American Academy of Dermatology (AAD) Annual Meeting: Diagnostic Complexity, Therapeutic Advances, and Emerging Research

VIEW
A man in a suit smiles at the camera next to text that reads, World Psoriasis Experts Give Their Take on Current, Hot, or Controversial Topics like Biologics in Psoriasis Management. EXPERT COMMENTARY.

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

VIEW

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.
Subscribe

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »
Monday, April 27, 2026

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026